Glactone Pharma develops novel drugs that target STAT3, a key transcription factor signaling pathway, for the treatment of advanced and drug resistant cancers to improve the lives of cancer patients.

Glactone Pharma AB

Our vision

We strive to build strong science and robust data to deliver real and meaningful benefits to patients. Learn more about our projects.

Our mission

We develop unique small-molecule inhibitors of STAT3 (Signal Transducer and Activator of Transcription 3) to enhance the efficacy and response of immunotherapies in immuno-oncology and for the treatment of advanced drug resistant cancers.

News & press releases

Archive >

Glactone Pharma: STAT3 interacts with the androgen receptor and is a drug target in enzalutamide resistant prostate cancer

2018-11-27

In collaboration with researchers at Vancouver Prostate Centre in Canada, Glactone Pharma has discovered a novel way of... [Read more]

Glactone Pharma: STAT3 interagerar med androgenreceptorn och är en läkemedelsmåltavla i enzalutamide-resistent prostatacancer

2018-11-27

I samarbete med forskare vid Vancouver Prostate Centre i Kanada har Glactone Pharma upptäckt ett nytt sätt att... [Read more]